- Home
- SLRX vs BDRX Comparison
SLRX vs BDRX Comparison
Compare SLRX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- BDRX
- Stock Information
- Founded
- SLRX N/A
- BDRX 2000
- Country
- SLRX United States
- BDRX United Kingdom
- Employees
- SLRX N/A
- BDRX 13
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- BDRX Health Care
- Exchange
- SLRX Nasdaq
- BDRX Nasdaq
- Market Cap
- SLRX 2.9M
- BDRX 3.9M
- IPO Year
- SLRX N/A
- BDRX N/A
- Fundamental
- Price
- SLRX $4.56
- BDRX $6.71
- Analyst Decision
- SLRX
- BDRX
- Analyst Count
- SLRX 0
- BDRX 0
- Target Price
- SLRX N/A
- BDRX N/A
- AVG Volume (30 Days)
- SLRX 286.4K
- BDRX 53.1K
- Earning Date
- SLRX 11-13-2025
- BDRX 09-23-2025
- Dividend Yield
- SLRX N/A
- BDRX N/A
- EPS Growth
- SLRX N/A
- BDRX N/A
- EPS
- SLRX N/A
- BDRX N/A
- Revenue
- SLRX N/A
- BDRX N/A
- Revenue This Year
- SLRX N/A
- BDRX N/A
- Revenue Next Year
- SLRX N/A
- BDRX N/A
- P/E Ratio
- SLRX N/A
- BDRX N/A
- Revenue Growth
- SLRX N/A
- BDRX N/A
- 52 Week Low
- SLRX $4.50
- BDRX $5.00
- 52 Week High
- SLRX $108.00
- BDRX $108.90
- Technical
- Relative Strength Index (RSI)
- SLRX 35.20
- BDRX 55.69
- Support Level
- SLRX $4.79
- BDRX $5.81
- Resistance Level
- SLRX $5.90
- BDRX $6.47
- Average True Range (ATR)
- SLRX 0.41
- BDRX 0.51
- MACD
- SLRX 0.20
- BDRX 0.22
- Stochastic Oscillator
- SLRX 19.46
- BDRX 81.44
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.